DexCom (NASDAQ:DXCM – Free Report) had its price objective boosted by Wells Fargo & Company from $90.00 to $94.00 in a report ...

while RBC Capital lowered its price target but kept an Outperform rating. DexCom also launched its new Stelo product and submitted its 15-day wear G7 to the FDA for review. Analysts anticipate ...

DexCom (NASDAQ:DXCM – Get Free Report) had its target price increased by stock analysts at Canaccord Genuity Group from $89.00 to $99.00 in a research report issued to clients and investors on Monday, ...

Starting today, Dexcom G7 continuous glucose monitor (CGM) users will be able to monitor their real-time blood sugar data straight from an Apple Watch. According to Dexcom’s press release ...

Dexcom has expanded access to its ground-breaking real-time CGM technology by introducing its best-in-class G7 sensor into 16 new markets. Patients with diabetes of any kind, including gestational ...

Canaccord analyst William Plovanic raised the firm’s price target ... time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on DXCM ...

Raymond James lowered the firm’s price target ... real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on DXCM: DexCom ...